ArticleTransboundary and emerging diseases2026
Prevention of Porcine Epidemic Diarrhea Virus With Nanotube-Adjuvanted Oral DNA Vaccines.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Overcoming Antigenic Drift in PEDV: Broadly Protective Antigen Design and sIgA-Driven Lactogenic Immunity.Veterinary sciences · 2026Review
- Prevention of Porcine Epidemic Diarrhea Virus With Nanotube-Adjuvanted Oral DNA Vaccines.Transboundary and emerging diseases · 2026Article
- Genetic Diversity, Recombination, and Pathogenicity of Porcine Epidemic Diarrhea Virus Strains Circulating in China During 2023-2024.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV) causes severe diarrhea in piglets. The ideal route of protection against PEDV for piglets is through passive (lactogenic) immunity, which is not provided by current inactivated and subunit vaccines on the market. In this study, we investigated whether a DNA vaccine encoding the full PEDV spike protein adjuvanted with cyclo-peptide nanotubes (cPNTs) can provide protection against PEDV through active and passive immunity. For the active immunization experiment, piglets were vaccinated, and the immune response was analyzed, followed by a PEDV challenge test. In a separate experiment, to evaluate the passive (lactogenic) immunity elicited by the cPNTs-adjuvanted DNA vaccine, pregnant sows in a local farm were immunized, and the survival of farrowed piglets was examined. The results showed that, in the active immunization experiment, the DNA vaccine elicited IFN-γ and IL-12 production in piglets. IgA antibodies were detected in the serum, and the expansion of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.